Crestor vs Losartan: Can You Switch Between Them?

Why These Two Drugs Get Compared

Patients searching "Crestor vs Losartan" often take one and wonder whether the other would serve them better. The confusion is understandable: both medications are prescribed for cardiovascular protection, both are daily pills, and both appear on the same cardiometabolic medication lists. But they operate through entirely different biological mechanisms.

Rosuvastatin (brand name Crestor) inhibits HMG-CoA reductase, the enzyme responsible for cholesterol synthesis in the liver. By blocking this enzyme, rosuvastatin lowers circulating LDL cholesterol by 36% to 52% depending on dose. LDL reduction is the primary reason statins prevent atherosclerotic cardiovascular disease (ASCVD), including heart attacks and ischemic strokes.

Losartan blocks the angiotensin II type 1 (AT1) receptor, preventing the vasoconstrictive and aldosterone-stimulating effects of angiotensin II. The result: lower blood pressure, reduced cardiac afterload, and protection against end-organ damage in the kidneys and heart. The 2017 ACC/AHA hypertension guideline lists ARBs as one of four first-line classes for essential hypertension.

Asking which is "better" misses the point. A patient with isolated hyperlipidemia and normal blood pressure needs rosuvastatin, not losartan. A patient with isolated hypertension and normal cholesterol needs losartan (or another antihypertensive), not a statin. A patient with both conditions may need both drugs.

What the Landmark Trials Actually Showed

The strongest evidence for each drug comes from large, randomized, controlled trials. No head-to-head trial has ever compared rosuvastatin directly against losartan because such a comparison would be clinically meaningless. They treat different diseases.

The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin), published in the New England Journal of Medicine in 2008, enrolled 17,802 apparently healthy men and women with LDL cholesterol <130 mg/dL but high-sensitivity C-reactive protein (hsCRP) of 2.0 mg/L or higher. Rosuvastatin 20 mg daily reduced the primary endpoint of major cardiovascular events by 44% (HR 0.56, 95% CI 0.46 to 0.69, P<0.00001). The trial was stopped early at a median of 1.9 years because the benefit was so clear.

The LIFE trial (Losartan Intervention For Endpoint reduction in hypertension), published in The Lancet in 2002, randomized 9,193 patients with essential hypertension and left ventricular hypertrophy to losartan-based or atenolol-based therapy. After a mean follow-up of 4.8 years, losartan reduced the composite endpoint (cardiovascular death, stroke, or myocardial infarction) by 13% (adjusted HR 0.87, P=0.021). The stroke reduction was particularly notable at 25%.

These trials answered different questions. JUPITER asked: does lowering inflammation and LDL in statin-naive, normolipidemic adults prevent cardiovascular events? LIFE asked: is losartan superior to atenolol for preventing CV events in hypertensive patients with left ventricular hypertrophy? Comparing the 44% relative risk reduction from JUPITER with the 13% from LIFE and concluding that Crestor is "better" is a statistical error. The populations, comparators, and endpoints differed completely.

Mechanism of Action: Different Targets, Different Results

Understanding why these drugs cannot substitute for each other requires a closer look at what each one does inside the body.

Rosuvastatin enters hepatocytes and competitively inhibits HMG-CoA reductase. The liver compensates by upregulating LDL receptors on its surface, pulling more LDL particles out of the bloodstream. The net effect is a dose-dependent LDL reduction. At the 10 mg dose, expect roughly a 45% drop in LDL-C; at 40 mg, up to 55%. Rosuvastatin also modestly raises HDL (by 8% to 14%) and lowers triglycerides (by 10% to 35%).

Losartan works at the AT1 receptor in vascular smooth muscle, the adrenal cortex, and the kidneys. Blocking angiotensin II at this receptor relaxes blood vessels, reduces aldosterone secretion, and promotes sodium excretion. The typical blood pressure reduction with losartan 50 to 100 mg daily is 5.5 to 10.5 mmHg systolic. Losartan also has a unique uricosuric property among ARBs, lowering serum uric acid, which may benefit patients with gout.

A statin does not lower blood pressure in any clinically meaningful way. An ARB does not lower LDL cholesterol. There is no pharmacologic overlap.

When Patients Take Both Drugs Together

The most common clinical scenario is not "Crestor or losartan" but "Crestor and losartan." Metabolic syndrome, which the American Heart Association defines as a cluster of at least three of five risk factors (abdominal obesity, high triglycerides, low HDL, elevated blood pressure, and high fasting glucose), frequently demands treatment of both dyslipidemia and hypertension.

The 2018 AHA/ACC cholesterol guideline recommends statin therapy for four patient groups: those with clinical ASCVD, those with LDL 190 mg/dL or higher, diabetic adults aged 40 to 75, and adults aged 40 to 75 with estimated 10-year ASCVD risk of 7.5% or greater. Many of these same patients also meet criteria for antihypertensive therapy. Dr. Paul Whelton, lead author of the 2017 ACC/AHA hypertension guideline, stated: "Blood pressure and cholesterol management often need to happen in parallel because the underlying vascular risk is driven by both."

There is no pharmacokinetic interaction between rosuvastatin and losartan that would prevent co-administration. Rosuvastatin is minimally metabolized by cytochrome P450 2C9 and is primarily excreted unchanged by the liver. Losartan is metabolized by CYP2C9 and CYP3A4 to its active metabolite E-3174. The shared CYP2C9 pathway raises a theoretical concern, but clinical data and FDA prescribing information show no dose adjustment is needed.

What "Switching" Actually Means Clinically

When a patient asks about switching from Crestor to losartan (or vice versa), the conversation with a prescriber usually reveals one of three situations.

Situation 1: The patient wants to stop one drug and start the other. This is not a switch. It is discontinuing treatment for one condition and beginning treatment for a different condition. If a patient stops rosuvastatin, LDL cholesterol will return to pre-treatment levels within two to four weeks. If LDL management was indicated, that risk is now unmanaged.

Situation 2: The patient is experiencing side effects from one drug and mistakenly believes the other is an alternative. Statin-associated muscle symptoms occur in roughly 7% to 29% of patients depending on the definition used. But switching to losartan does not address the underlying lipid problem. The correct approach for statin intolerance is trying a different statin, a lower dose, alternate-day dosing, or adding ezetimibe or a PCSK9 inhibitor.

Situation 3: The patient needs both drugs but is currently only on one. This is an addition, not a switch. A prescriber might add losartan to an existing rosuvastatin regimen when blood pressure readings consistently exceed 130/80 mmHg, per the ACC/AHA threshold.

None of these scenarios involves a true pharmacologic substitution.

Side Effect Profiles: What to Expect From Each

Rosuvastatin and losartan have distinct adverse effect patterns, which matters when patients attribute symptoms to the wrong medication.

Rosuvastatin's most reported side effects include myalgia (muscle pain without CK elevation), headache, nausea, and abdominal pain. Serious but rare risks include rhabdomyolysis (estimated incidence 1.6 per 100,000 patient-years across all statins), new-onset type 2 diabetes (risk increase of roughly 9% in meta-analyses), and hepatotoxicity signaled by transaminase elevations above three times the upper limit of normal.

Losartan's common side effects are dizziness, upper respiratory infection, nasal congestion, and back pain. The class-wide ARB risk is hyperkalemia, particularly in patients with chronic kidney disease (CKD) or those taking potassium-sparing diuretics. ARBs also carry a black-box warning against use in pregnancy due to fetal renal toxicity. Unlike ACE inhibitors, ARBs rarely cause dry cough, which is one reason clinicians switch patients from lisinopril or enalapril to losartan.

A 2019 meta-analysis of ARB safety in the Cochrane Database found that losartan and other ARBs were no more likely to cause withdrawal due to adverse events than placebo. Rosuvastatin also showed low discontinuation rates in JUPITER: 75.6% of rosuvastatin patients remained on therapy at the end of the trial versus 75.4% on placebo.

Cost and Access Considerations

Generic rosuvastatin became available in the US in 2016, and a 30-day supply of rosuvastatin 10 mg typically costs $4 to $15 at most pharmacies with a discount card. Generic losartan has been available since 2010 and costs roughly $3 to $10 for a 30-day supply of the 50 mg tablet.

Both drugs are on the $4 generic lists at major retail pharmacies. Both are covered by virtually all commercial insurance formularies, Medicare Part D plans, and Medicaid programs. The GoodRx pricing data consistently shows these among the most affordable cardiovascular medications in the United States.

Brand-name Crestor (AstraZeneca) still exists but offers no clinical advantage over generic rosuvastatin. The FDA requires generic drugs to demonstrate bioequivalence within an 80% to 125% confidence interval for AUC and Cmax. If cost is a concern, generic formulations of both drugs are clinically equivalent to their branded counterparts.

Monitoring Requirements Differ

Patients on rosuvastatin need a baseline lipid panel before starting therapy and a follow-up lipid panel at 4 to 12 weeks to assess response. The 2018 ACC/AHA guideline on cholesterol management recommends checking fasting lipids annually thereafter. Liver function tests (ALT) should be checked at baseline, though routine monitoring is no longer mandated unless symptoms develop. CK levels are only checked if the patient reports muscle symptoms.

Losartan monitoring focuses on blood pressure, serum creatinine, and potassium. The JNC 8 panel and subsequent ACC/AHA guidelines recommend checking renal function and electrolytes within two to four weeks of starting an ARB or after dose increases. Patients with CKD stage 3 or higher require more frequent monitoring because ARBs can worsen hyperkalemia and cause acute kidney injury if renal perfusion is compromised.

A patient taking both drugs will need both sets of labs, but the blood draws can usually be combined into a single annual cardiometabolic panel.

Special Populations and Considerations

Certain patient groups face unique considerations when prescribed either drug.

Patients with diabetes: The ADA Standards of Care 2024 recommends moderate- or high-intensity statin therapy for all diabetic adults aged 40 to 75. Losartan is preferred over some other antihypertensives in diabetics with microalbuminuria because ARBs slow progression of diabetic nephropathy. A landmark trial, RENAAL (N=1,513), showed losartan reduced the risk of doubling of serum creatinine by 25% compared to placebo in type 2 diabetics with nephropathy.

Patients with CKD: Rosuvastatin requires dose adjustment at GFR <30 mL/min (maximum 10 mg daily in severe renal impairment). Losartan does not require renal dose adjustment but demands close potassium and creatinine monitoring in CKD stages 4 and 5.

Older adults: Both drugs are listed as appropriate in the 2023 AGS Beers Criteria update without specific age-related warnings, though statin initiation for primary prevention in patients over 75 remains a shared decision between patient and physician.

Pregnancy: Rosuvastatin is contraindicated. The FDA reclassified all statins as contraindicated in pregnancy in 2021. Losartan is also contraindicated, carrying a black-box warning for fetal harm including renal agenesis and oligohydramnios. Pregnant patients needing blood pressure control are typically switched to labetalol, nifedipine, or methyldopa.

How Your Doctor Decides What You Need

The decision tree is straightforward. It does not involve choosing between these drugs as competitors.

If LDL-C is above goal (based on 10-year ASCVD risk calculation), a statin is indicated. Rosuvastatin is commonly chosen for patients needing 50% or greater LDL reduction because it is the highest-potency statin at equivalent doses, according to the ACC/AHA intensity classification.

If blood pressure is consistently at or above 130/80 mmHg with confirmed out-of-office readings, antihypertensive therapy is indicated. Losartan may be selected, especially in patients who also have diabetes with proteinuria, heart failure with reduced ejection fraction, or a history of ACE inhibitor-associated cough.

If both lipids and blood pressure are abnormal, both drugs are prescribed. A 2020 analysis from the National Health and Nutrition Examination Survey (NHANES) estimated that 45.4% of US adults have hypertension and 28.5% have hypercholesterolemia, with substantial overlap. Treating one risk factor while ignoring the other leaves residual cardiovascular risk on the table.

The prescribing physician will review labs, vital signs, medication history, and comorbidities before starting or changing either drug. Patients should not self-switch between rosuvastatin and losartan based on internet comparisons.